Company news
Clene Inc. news in 2025
Clene Inc.'s news releases, calls and decks from 2025, newest first.
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
December 3, 2025
Clene to Provide CNM-Au8® ALS Program Update
December 2, 2025
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
November 20, 2025
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
November 13, 2025
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
October 15, 2025
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
September 25, 2025
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
September 4, 2025
Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
August 14, 2025
Clene to Present at the Canaccord 45th Annual Growth Conference
August 5, 2025
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
June 30, 2025
Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025
June 8, 2025
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
May 7, 2025
Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
May 7, 2025
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
April 8, 2025
Clene to Present at the Jones Healthcare and Technology Innovation Conference
April 1, 2025
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025
March 24, 2025
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
March 24, 2025
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
March 12, 2025
Clene to Present at the 37TH Annual Roth Conference
March 6, 2025
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11
February 26, 2025
Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction
February 25, 2025
Decks in 2025
- Corporate Update (October 2025)
Corporate update · 32 slides · Oct 14, 2025